Zacks Research Has Positive View of Integer FY2024 Earnings

Integer Holdings Co. (NYSE:ITGR) – Stock analysts at Zacks Research lifted their FY2024 earnings estimates for Integer in a research report issued on Thursday, November 14th. Zacks Research analyst D. Dey now forecasts that the medical equipment provider will post earnings per share of $5.32 for the year, up from their previous forecast of $5.28. The consensus estimate for Integer’s current full-year earnings is $5.34 per share. Zacks Research also issued estimates for Integer’s Q4 2024 earnings at $1.45 EPS, Q1 2025 earnings at $1.30 EPS, Q2 2025 earnings at $1.45 EPS, Q4 2025 earnings at $1.69 EPS, FY2025 earnings at $5.99 EPS, Q1 2026 earnings at $1.63 EPS and Q2 2026 earnings at $1.57 EPS.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.07. Integer had a net margin of 6.70% and a return on equity of 11.63%. The business had revenue of $431.42 million for the quarter, compared to analysts’ expectations of $440.59 million. During the same quarter in the prior year, the company earned $1.27 earnings per share. The business’s revenue was up 8.7% compared to the same quarter last year.

Several other brokerages also recently commented on ITGR. Benchmark increased their target price on Integer from $130.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Truist Financial dropped their price objective on Integer from $150.00 to $147.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Piper Sandler reissued an “overweight” rating and issued a $140.00 target price (up previously from $125.00) on shares of Integer in a research report on Friday, October 25th. Citigroup raised their price target on shares of Integer from $124.00 to $130.00 and gave the company a “neutral” rating in a report on Tuesday, October 1st. Finally, KeyCorp boosted their price objective on shares of Integer from $139.00 to $144.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $139.75.

Integer Price Performance

Shares of NYSE:ITGR opened at $134.55 on Monday. The company has a market capitalization of $4.51 billion, a PE ratio of 41.10, a PEG ratio of 1.91 and a beta of 1.09. The business has a fifty day moving average price of $129.20 and a 200-day moving average price of $122.75. Integer has a 1-year low of $84.75 and a 1-year high of $140.91. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09.

Institutional Investors Weigh In On Integer

Institutional investors have recently bought and sold shares of the business. Contravisory Investment Management Inc. raised its position in shares of Integer by 55.9% during the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 80 shares during the last quarter. Huntington National Bank boosted its holdings in shares of Integer by 8,933.3% during the 3rd quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 268 shares during the last quarter. Quest Partners LLC boosted its holdings in shares of Integer by 3,688.9% during the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 332 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Integer by 60.9% during the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 142 shares in the last quarter. Finally, Innealta Capital LLC bought a new stake in shares of Integer in the second quarter worth about $110,000. Hedge funds and other institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.